Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07352423 | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants | PHASE1 | RECRUITING | 48 | — | — | Mar 26, 2026 | Dec 23, 2026 | Apr 9, 2026 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will be enrolled across multiple cohorts and will receive a single dose of placebo. |
| ALXN2230 | EXPERIMENTAL | Participants will be enrolled across multiple cohorts and will receive a single dose of ALXN2230. |
| Name | Type | Description |
|---|---|---|
| ALXN2230 | DRUG | Participants will receive ALXN2230 via SC injection. Optional cohort will receive ALXN2230 via SC infusion. |
| Placebo | DRUG | Participants will receive placebo via SC injection. Optional cohort will receive placebo via SC infusion. |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Baseline immunoglobulin G (IgG) concentrations ≥ 1000 milligrams per deciliter (mg/dL) and ≤ 1600 mg/dL at Scre...